Malignant Neoplasm Clinical Trial
Official title:
Perioperative Ostomy Self-Management Telehealth (Periop-OSMT) for Cancer Patients and Family Caregivers
Verified date | May 2023 |
Source | City of Hope Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase II trial studies how well Perioperative Ostomy Self-Management Telehealth (Periop-OSMT) provides patients and their caregivers information about ostomy and ostomy care. Periop-OSMT may help to understand patient preparedness to do ostomy self-care, confidence in doing ostomy self-care, knowledge of ostomy self-care, quality of life, mood, use of medical services, and financial burden.
Status | Completed |
Enrollment | 6 |
Est. completion date | May 12, 2021 |
Est. primary completion date | May 12, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - PATIENT: Scheduled to undergo a surgical procedure that includes the creation of an intestinal stoma (fecal or urinary). - PATIENT: Able to read and understand English. - PATIENT: Patients scheduled for temporary ostomy procedures - SUPPORT PERSON/FCG: Family member/friend identified by the patient as the primary caregiver before and after surgery. - SUPPORT PERSON/FCG: Able to read and understand English. - Patients with all stages of disease are eligible for the study. - The study is open to anyone regardless of gender or ethnicity. Efforts are made to extend the accrual to a representative population. Exclusion Criteria: - Subjects, who in the opinion of the principal investigator (PI), may not be able to comply with the requirements of the study. |
Country | Name | City | State |
---|---|---|---|
United States | City of Hope Medical Center | Duarte | California |
United States | University of Pennsylvania/Abramson Cancer Center | Philadelphia | Pennsylvania |
United States | Banner University Medical Center - Tucson | Tucson | Arizona |
Lead Sponsor | Collaborator |
---|---|
City of Hope Medical Center | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Patient and family caregiver (FCG) participation | Assessed by ratio of eligible participants (patient and FCGs) to those enrolled and those who decline participation, reasons for non-participation, number of scheduled study encounters completed, attrition rate between pre- and post-intervention, reasons for attrition/dropout, level of intervention participation including the total number of sessions, number of sessions completed without break-offs, number of break-offs, length (minutes) of sessions, and the ratio of all participants to those who completed >= 80% of the study. | Up to 24 months | |
Secondary | Patient reported outcomes | Will be examined pre- and post-intervention, including patient activation, self-efficacy, ostomy-related knowledge, health related quality of life, medical care utilization, and financial burden. Descriptive statistics will be summarized using validated scoring procedures. The data will be used to assess descriptively the trajectory and patterns of outcomes before and after the intervention. | Up to 6 months post-discharge | |
Secondary | Support person/FCG reported outcomes | Will be examined pre- and post-intervention, including quality of life. Descriptive statistics will be summarized using validated scoring procedures. The data will be used to assess descriptively the trajectory and patterns of outcomes before and after the intervention. | Up to 6 months post-discharge | |
Secondary | Acceptability of Perioperative Ostomy Self-Management Telehealth | Acceptability will be assessed through qualitative data analysis using the conventional content analysis approach. Data from the tape-recorded interviews are transcribed and analyzed using HyperRESEARCH software. Transcripts will be imported for the development of analytic categories, data coding, and review of coded data. All data will be read repeatedly to achieve immersion and obtain a sense of the whole. Then, data will be read word by word to derive codes. Codes will be then sorted into themes based on links and relationship. Separate investigators will conduct a final validation review of the codes and themes to ensure consistency and clarity across all qualitative data. Data discordantly coded will be discussed for refinement and consensus purposes. | Up to 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02243592 -
Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment
|
||
Completed |
NCT03445572 -
Meditative Slow Breathing or Isha Kriya Meditation in Improving Cancer-Related Symptoms in Hospitalized Participants With Cancer
|
N/A | |
Active, not recruiting |
NCT02860039 -
High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant
|
Phase 2 | |
Completed |
NCT01946217 -
Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials
|
N/A | |
Completed |
NCT01635413 -
Group Exercise Training for Functional Improvement After Treatment (The GET FIT Trial)
|
N/A | |
Completed |
NCT00026169 -
Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure
|
Phase 1 | |
Recruiting |
NCT04534075 -
Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial
|
Phase 3 | |
Active, not recruiting |
NCT01806129 -
Reproductive Health Program in Patients With Cancer
|
N/A | |
Recruiting |
NCT03915717 -
Observational Study of Outcomes After EchoMark and EchoSure-based Free Flap Monitoring
|
||
Recruiting |
NCT02280161 -
Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer
|
||
Recruiting |
NCT05520281 -
Short-term Psychodynamic Psychotherapy in Serious Physical Illness
|
N/A | |
Terminated |
NCT00532064 -
Cardiac Biomarkers in Early Detection of Cardiotoxicity in Patients Receiving Sunitinib or Sorafenib Chemotherapy
|
||
Completed |
NCT04990882 -
FAPI PET/CT Prospective Interobserver Agreement
|
||
Completed |
NCT01896778 -
Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer
|
N/A | |
Recruiting |
NCT05770102 -
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
|
Phase 2/Phase 3 | |
Recruiting |
NCT06090266 -
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Recruiting |
NCT05886764 -
Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials
|
N/A | |
Completed |
NCT01432431 -
Spiritual Care in Improving Quality of Life of Patients, Caregivers, and Hospital Staff
|
N/A | |
Completed |
NCT01506440 -
Cognitive Assessments in Patients With Cancer Undergoing Chemotherapy
|